Thiazolidinediones
H Yki-Järvinen - New England Journal of Medicine, 2004 - Mass Medical Soc
New England Journal of Medicine, 2004•Mass Medical Soc
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes,
very few agents have been introduced during the past 20 years. The thiazolidinediones
represent a potentially important new group of drugs with a mechanism of action differing
from and perhaps complementary to that of existing therapies. This article discusses present
data on mechanisms, indications, and limitations of thiazolidinedione therapy.
very few agents have been introduced during the past 20 years. The thiazolidinediones
represent a potentially important new group of drugs with a mechanism of action differing
from and perhaps complementary to that of existing therapies. This article discusses present
data on mechanisms, indications, and limitations of thiazolidinedione therapy.
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes, very few agents have been introduced during the past 20 years. The thiazolidinediones represent a potentially important new group of drugs with a mechanism of action differing from and perhaps complementary to that of existing therapies. This article discusses present data on mechanisms, indications, and limitations of thiazolidinedione therapy.
The New England Journal Of Medicine